Close

Vical (VICL) Issues Update on CyMVectin Preclinical Studies

April 21, 2015 6:37 AM EDT Send to a Friend
Vical (NASDAQ: VICL) announced that Michael McVoy, Ph.D., Professor of Pediatrics at Virginia Commonwealth University, presented data from preclinical studies ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login